JP6499965B2 - Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 - Google Patents
Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 Download PDFInfo
- Publication number
- JP6499965B2 JP6499965B2 JP2015530537A JP2015530537A JP6499965B2 JP 6499965 B2 JP6499965 B2 JP 6499965B2 JP 2015530537 A JP2015530537 A JP 2015530537A JP 2015530537 A JP2015530537 A JP 2015530537A JP 6499965 B2 JP6499965 B2 JP 6499965B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- acid
- free
- cosmetic composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 188
- 239000002537 cosmetic Substances 0.000 title claims description 85
- 238000004519 manufacturing process Methods 0.000 title 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 149
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 149
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 99
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 27
- 206010000496 acne Diseases 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 25
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 24
- 229960002733 gamolenic acid Drugs 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 21
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000002562 thickening agent Substances 0.000 claims description 17
- 239000002304 perfume Substances 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 239000003755 preservative agent Substances 0.000 claims description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 13
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 13
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 13
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003463 adsorbent Substances 0.000 claims description 12
- 229960005323 phenoxyethanol Drugs 0.000 claims description 12
- 239000003352 sequestering agent Substances 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 229940075529 glyceryl stearate Drugs 0.000 claims description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 10
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 9
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 9
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 8
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 8
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 8
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 claims description 8
- 235000021588 free fatty acids Nutrition 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 235000014121 butter Nutrition 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 7
- 229960000735 docosanol Drugs 0.000 claims description 6
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 5
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 claims description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 5
- 229960004889 salicylic acid Drugs 0.000 claims description 5
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- ATNNLHXCRAAGJS-QZQOTICOSA-N (e)-docos-2-enoic acid Chemical compound CCCCCCCCCCCCCCCCCCC\C=C\C(O)=O ATNNLHXCRAAGJS-QZQOTICOSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- FPAQLJHSZVFKES-UHFFFAOYSA-N 5-Eicosenoic acid Natural products CCCCCCCCCCCCCCC=CCCCC(O)=O FPAQLJHSZVFKES-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- -1 softeners Substances 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229940083608 sodium hydroxide Drugs 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 60
- 210000003491 skin Anatomy 0.000 description 55
- 238000000034 method Methods 0.000 description 26
- 241000186427 Cutibacterium acnes Species 0.000 description 22
- 230000003078 antioxidant effect Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 235000019645 odor Nutrition 0.000 description 19
- 238000005259 measurement Methods 0.000 description 17
- 229940055019 propionibacterium acne Drugs 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000003002 pH adjusting agent Substances 0.000 description 11
- 230000002335 preservative effect Effects 0.000 description 11
- WHBKVWBGTBULQY-UHFFFAOYSA-N 2-propylheptyl octanoate Chemical compound CCCCCCCC(=O)OCC(CCC)CCCCC WHBKVWBGTBULQY-UHFFFAOYSA-N 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229940008099 dimethicone Drugs 0.000 description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 description 10
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000004342 Benzoyl peroxide Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 235000019400 benzoyl peroxide Nutrition 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000000245 forearm Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- WMPGRAUYWYBJKX-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WMPGRAUYWYBJKX-UHFFFAOYSA-N 0.000 description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229940094332 peg-8 dimethicone Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004902 Softening Agent Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 3
- 238000012623 in vivo measurement Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004011 methenamine Drugs 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010611 checkerboard assay Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- UOORRWUZONOOLO-OWOJBTEDSA-N (E)-1,3-dichloropropene Chemical compound ClC\C=C\Cl UOORRWUZONOOLO-OWOJBTEDSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 description 1
- DXTKRPKKCMBXGZ-UHFFFAOYSA-N 1-[1-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-3-[[[1-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]carbamoylamino]methyl]urea Chemical compound O=C1N(CO)C(=O)NC1NC(=O)NCNC(=O)NC1C(=O)N(CO)C(=O)N1 DXTKRPKKCMBXGZ-UHFFFAOYSA-N 0.000 description 1
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- TYBHZVUFOINFDV-UHFFFAOYSA-N 2-bromo-6-[(3-bromo-5-chloro-2-hydroxyphenyl)methyl]-4-chlorophenol Chemical compound OC1=C(Br)C=C(Cl)C=C1CC1=CC(Cl)=CC(Br)=C1O TYBHZVUFOINFDV-UHFFFAOYSA-N 0.000 description 1
- PUSPAPGHKSLKKH-UHFFFAOYSA-N 2-methyl-1,2-thiazolidin-3-one Chemical compound CN1SCCC1=O PUSPAPGHKSLKKH-UHFFFAOYSA-N 0.000 description 1
- PKLPQOJFHFGVBS-UHFFFAOYSA-N 3-acetyl-4-hydroxy-6-methyl-2h-pyran-2-one Chemical compound CC(=O)C1=C(O)C=C(C)OC1=O PKLPQOJFHFGVBS-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- LQAMWLCPFJZSSU-UHFFFAOYSA-N 7a-ethyl-1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazole;pentanedial Chemical compound O=CCCCC=O.C1OCN2COCC21CC LQAMWLCPFJZSSU-UHFFFAOYSA-N 0.000 description 1
- 208000030560 Abnormality of the skin Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000186892 Aloe vera Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- VEZBVUBAOBLGTQ-UHFFFAOYSA-N C(O)CN.ON1C(C=C(C=C1C1=C(CC(C=C1)(C)C)C)C)=O Chemical compound C(O)CN.ON1C(C=C(C=C1C1=C(CC(C=C1)(C)C)C)C)=O VEZBVUBAOBLGTQ-UHFFFAOYSA-N 0.000 description 1
- 208000001348 Chloracne Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101000666370 Homo sapiens Transcription factor Dp-1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010027026 Mechanical acne Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102100038130 Transcription factor Dp-1 Human genes 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000005298 biophysical measurement Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 239000000182 glucono-delta-lactone Substances 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- SBHCLVQMTBWHCD-UHFFFAOYSA-N icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(O)=O SBHCLVQMTBWHCD-UHFFFAOYSA-N 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical class [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 description 1
- PETXWIMJICIQTQ-UHFFFAOYSA-N phenylmethoxymethanol Chemical compound OCOCC1=CC=CC=C1 PETXWIMJICIQTQ-UHFFFAOYSA-N 0.000 description 1
- OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004439 roughness measurement Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本願は、2012年9月6日出願の米国仮特許出願第61/697,631号の利益を主張する2013年5月31日出願の米国特許出願第13/906,67号の継続出願であり、これら各出願の開示内容は、その全体が参照により本明細書に援用される。
本開示は、一般に、遊離エイコサペンタエン酸及び遊離ガンマリノレン酸を含む化粧品組成物、並びにその製造方法及び使用方法に関する。
上記記載の方法に従って、表1に列挙された構成成分を合わせることにより局所用組成物を調製した。EPA遊離酸は、98.1重量%のEPA遊離酸を含む組成物の形態で提供され、GLA遊離酸は、70.2重量%のGLA遊離酸を含む組成物の形態で提供された。EPA及びGLAの値は、それから各々が添加された組成物の純度を反映する値である。最終処方物は、次のとおり、下記の表1に示した組成を有した。
上記記載の方法に従って、表2に列挙された成分を合わせることによって局所用組成物を調製した。EPA遊離酸は、98.1重量%のEPA遊離酸を含む組成物の形態で提供され、GLA遊離酸は、70.2重量%のGLA遊離酸を含む組成物の形態で提供された。EPA及びGLAの値は、それから各々が添加された組成物の純度を反映する値である。最終処方物は、次のとおり、下記の表2に示した組成を有した。
局所用組成物を、主容器内で水、グリセリン及びEDTA二ナトリウムを合わせ、70〜70℃に加熱することによって調製した。混合物を加熱している間に、増粘剤(ポリアクリル酸ナトリウム)を加え、高速で15分間均質化した。第2の容器で、乳化剤及び軟化剤を合わせ、70〜75℃に加熱した。次いで融解した乳化剤及び軟化剤を主容器に加え、15分間均質化した。この混合物を25℃に冷却した。吸着剤を50℃に加熱し、主容器に加えた。次いで防腐剤を35℃に加熱した後に、主容器に加えた。香料及び酸化防止剤を合わせ、その後主容器に加えた。pH調節剤を主容器に加え、続いてEPA及びGLAの混合物を加えた。
実施例1〜3の処方物A〜Cの塗布後の皮膚の酸化防止能を判定するための試験は、それぞれ35〜50歳の年齢の16人の男性及び女性の被験者を含む。掌側前腕部で色彩色差計測定を行い、各被験者の個々のトポグラフィー角度(「ITA°」)を特定する。次いで、6つの小さいスポットを、ITA°に依存する線量のUVA/UVB照射にさらす。24時間後に、各被験者の最小紅斑線量(「MED」)を評価する。
実施例1〜3の処方物A〜Cの効果を判定するための試験は、それぞれ35〜50歳の年齢の28人の男性及び女性の被験者を含む。掌側前腕部で色彩色差計測定を行い、各被験者の個々のトポグラフィー角度(「ITA°」)を特定する。次いで、6つの小さいスポットを、ITA°に依存する線量のUVA/UVB照射にさらす。24時間後に、各被験者の最小紅斑線量(「MED」)を評価する。この時点で、上皮厚み(例えば、Vivascope又は類似の機器により)、皮膚弾力(例えば、Cutometer又は類似の機器により)、皮膚の含水(例えば、Cornemeter又は類似の機器により)、及び肌荒れ/小じわ評価/三次元構造(例えば、Phase−shifted Rapid In vivo Measurement Of human Skin−「PRIMOS」−又は類似の機器の使用により)を含むベースラインの測定値も得る。
UVB及びUVA照射を放射する太陽光シミュレータによる反復される準紅斑線量の照射の際に、皮膚の乾燥及び肌荒れを予防するための処方物A〜Cの有効性を判定するための試験を行う。被験者は、それぞれがII型又はIII型の皮膚を有する14人の男性及び女性を含む。
肌荒れを低減するための本開示の組成物の有効性(しわを低減及び/又は予防するためのマーカとして)を判定するための試験を行った。
色彩色差計CM825(Courage & Khazaka,Cologne,ドイツ)で、静電容量法により皮膚角質層の含水量の測定を行った。この測定原理は、コンデンサとして機能する測定ヘッドの静電容量の変化に基づく。金で構成されるコンデンサの間に、電界が構築される。これらの手段により、上部皮膚層の比誘電率が測定される。比誘電率は、皮膚の水分含量に伴って変化するために、皮膚角質層の含水量を判定することができる。
皮膚表面状態、単一測定
太陽光シミュレータ(UVA Spot 1000、Filter H2 Honle,ドイツ)を用いて、試験領域への要求された照射強度で、試験領域の照射を行った。試験領域は、同時に照射されてもよい。
図1に示すように、EPA/GLA試験生成物は、UVに誘導される肌荒れをプラセボよりも有効に低減した。示したデータは、第1日目と比較した第15日目のものである。
材料及び方法
試験化合物及び細菌培養物
全ての細菌培養基及び試薬は、別途記載のない限り、Sigma−Aldrich Ltdから購入した。
BPO、FUS、NEO及びSAと組み合わせたEPA、GLA、及びGLA 70%の間の抗プロピオニバクテリウム・アクネス(P.acnes)相乗的相互作用の存在を観察するために、米国微生物学会(American Society for Microbiology)によって公開された標準プロトコル(American Society for Microbiology,1992)に従って、チェッカーボードアッセイを行った。各化合物の倍加希釈物を、SBB中で調製し、標準的チェッカーボードパターンで96−ウェルプレートに分配した。化合物の濃度は、≦1/16XMIC〜≧4XMICの範囲であった。ポジティブコントロールのウェルは、いずれかのウェルで使用された溶媒の最大容量を有するブロスを含有し、一方負の対照のウェルは、ブロスだけを含有した。接種物を、上記のとおり1×107 CFU/mLに調製した。各ウェル(ネガティブコントロールを除いて)を、5μLの細菌懸濁液で接種した。プレートを37℃で48時間、嫌気的にインキュベートし、次いで各ウェルを、ブロスの清澄度及び/又はウェル中のコロニーの存在に基づいて、増殖の有無を判定した。それぞれの薬物間相互作用の二通りのプレートからの最低ΣFIC値を用いて、それぞれの相互作用の性質がそれから評価される平均値を算定した。相乗効果はΣFIC≦0.5として定義される。いかなる細菌相互作用もチェックするために、目に見える増殖を含有しないそれぞれのウェルからの10μLを30℃で48時間にわたって嫌気的にインキュベートした。本報告書では、殺菌相乗効果は、作用物質の組み合わせが、化合物の累積MBCよりも低い組み合わせ濃度で、>99.9%の接種物を死滅させる場合に認められる。
プロピオニバクテリウム・アクネス(P.acnes)に対する試験作用物質の単独活性
プロピオニバクテリウム・アクネス(P.acnes)に対するEPA、GLA及びGLA 70%のMICは、64〜128mg/Lの範囲であったが、これら脂肪酸のいずれも、4096mg/Lまで細菌を死滅させなかった(表7)。SA及びBPOについてのMICは64mg/Lであったが、これら作用物質のいずれも4096mg/Lまで細菌を死滅させなかった。FUSのプロピオニバクテリウム・アクネス(P.acnes)に対するMIC及びMBCは、それぞれ2mg/L及び256mg/Lであり、NEOのMIC及びMBCは、それぞれ8mg/L及び16mg/Lであった(表7)。AZAは、4097mg/Lであっても、抗プロピオニバクテリウム・アクネス(P.acnes)活性を示さなかった(表7)。エタノール及びDMSOは、試験された最大濃度でも、プロピオニバクテリウム・アクネス(P.acnes)の増殖に及ぼす影響を有さなかった。GLA 70%は、GLA≧95%とまさに同程度有効であったことに留意することは重要である。
チェッカーボードアッセイを用いて、3つの脂肪酸(EPA、GLA、及びGLA 70%)と4つの従来の抗菌剤(BPO、NEO、FUS及びSA)との間の相乗効果を検出した。二通りのチェッカーボードのそれぞれに関する最低ΣFICを用いて、各相互作用についての平均ΣFICを算定した(表8)。プロピオニバクテリウム・アクネス(P.acnes)の抑制で正の相互作用/相乗効果を示した組み合わせは、EPAとSAとの組み合わせのみであった。
実施例1により調製された処方物A〜Cの組成の知覚される臭いを決定するために試験を行った。各組成物の少量を、4人の参加被験者の手の甲又は手首に無作為に塗布した。下記の表9に示すように、各被験者が、リカート型尺度に基づいて、「生臭い」臭いのレベルを数分間報告した。
Claims (21)
- 化粧品組成物であって、
遊離エイコサペンタエン酸と、
遊離ガンマリノレン酸と、
C12−15安息香酸アルキル、セテアリルイソノナノエート、ブチロスパーマム・パーキー・バター(butyrospermum parkii butter)、アスコルビルパルミテート、クエン酸ステアリン酸グリセリル、ステアリン酸グリセリル、ベヘニルアルコール、水酸化ナトリウム及びアルミニウムスターチ・オクテニルスクシネートを含む、化粧品的に許容可能な賦形剤と、を含む化粧品組成物であり、
前記遊離エイコサペンタエン酸と前記遊離ガンマリノレン酸が、2:1〜8:1の重量比で存在し、かつ
前記遊離エイコサペンタエン酸が、最大8重量%の量で存在する、化粧品組成物。 - 前記化粧品的に許容可能な賦形剤が、溶媒、封鎖剤、湿潤剤、増粘剤、乳化剤、軟化剤、吸着剤、防腐剤、香料、酸化防止剤、pH調節剤、テキスチャー化剤、及びこれらの組み合わせからなる群から選択される、請求項1に記載の化粧品組成物。
- 前記化粧品的に許容可能な賦形剤が、水、EDTA二ナトリウム、グリセリン、ポリアクリル酸ナトリウム、フェノキシエタノール及びエチルヘキシルグリセリン、ジメチルメトキシクロマノール、及び香料をさらに含む、請求項1に記載の化粧品組成物。
- 前記遊離エイコサペンタエン酸が、0.5重量%〜8重量%、0.8重量%〜4重量%、0.815重量%、1.631重量%、又は4.080重量%の量で存在する、請求項1〜3のいずれか一項に記載の化粧品組成物。
- 前記遊離ガンマリノレン酸は、0.1重量%〜3重量%、0.2重量%〜1.5重量%、0.285重量%、0.570重量%、又は1.425重量%の量で存在する、請求項1〜4のいずれか一項に記載の化粧品組成物。
- 前記遊離エイコサペンタエン酸が、0.815重量%の量で存在し、前記遊離ガンマリノレン酸が、0.285重量%の量で存在する、請求項1〜5のいずれか一項に記載の化粧品組成物。
- 前記遊離エイコサペンタエン酸が、1.631重量%の量で存在し、前記遊離ガンマリノレン酸が、0.570重量%の量で存在する、請求項1〜5のいずれか一項に記載の化粧品組成物。
- 前記遊離エイコサペンタエン酸が、4.080重量%の量で存在し、前記遊離ガンマリノレン酸が、1.425重量%の量で存在する、請求項1〜5のいずれか一項に記載の化粧品組成物。
- 前記遊離エイコサペンタエン酸が、少なくとも95重量%の遊離エイコサペンタエン酸を含む組成物に由来する、請求項1〜8のいずれか一項に記載の化粧品組成物。
- 前記遊離ガンマリノレン酸が、少なくとも70重量%の遊離ガンマリノレン酸を含む組成物に由来する、請求項1〜9のいずれか一項に記載の化粧品組成物。
- 前記遊離エイコサペンタエン酸が、少なくとも95重量%の遊離エイコサペンタエン酸を含む組成物に由来し、並びに前記遊離ガンマリノレン酸が、少なくとも70重量%の遊離ガンマリノレン酸を含む組成物に由来する、請求項1〜10のいずれか一項に記載の化粧品組成物。
- 前記遊離ガンマリノレン酸が、70重量%以上90重量%以下の遊離ガンマリノレン酸を含む組成物に由来する、請求項1〜10のいずれか一項に記載の化粧品組成物。
- 前記遊離ガンマリノレン酸が、少なくとも70重量%の遊離ガンマリノレン酸、並びにパルミチン酸、ステアリン酸、オレイン酸、リノール酸、イコセン酸、及びドコセン酸の遊離酸のうちの少なくとも1つを含む組成物に由来する、請求項1〜12のいずれか一項に記載の化粧品組成物。
- 前記化粧品組成物が、10重量%又は5重量%の前記化粧品組成物中に存在する全ての遊離脂肪酸を含む、請求項1〜13のいずれか一項に記載の化粧品組成物。
- 0.815重量%〜4.08重量%のEPAと、
0.285重量%〜1.425重量%のGLAと、
3.0重量%のグリセリンと、
0.1重量%のEDTA二ナトリウムと、
0.5重量%のポリアクリル酸ナトリウムと、
2重量%のクエン酸ステアリン酸グリセリルと、
3重量%のC12−15安息香酸アルキルと、
5重量%のセテアリルイソノナノエートと、
2重量%のステアリン酸グリセリルと、
1重量%のベヘニルアルコールと、
2重量%のブチロスパーマム・パーキー・バター(butyrospermum parkii butter)と、
1重量%のアルミニウムスターチ・オクテニルスクシネートと、
1重量%のフェノキシエタノール及びエチルヘキシルグリセリンと、
0.7重量%の香料と、
0.01重量%のジメチルメトキシクロマノールと、
0.01重量%のアスコルビルパルミテートと、
0.3重量%の水酸化ナトリウムと、
残部水と、を含む、請求項1に記載の化粧品組成物。 - 前記化粧品組成物が、化粧品的に許容可能な臭いを有する、請求項1〜15のいずれか一項に記載の化粧品組成物。
- サリチル酸を更に含む、請求項1〜16のいずれか一項に記載の化粧品組成物。
- 対象の皮膚の少なくとも一部の皮膚疾患又は状態を局所的に治療及び/又は予防するための、請求項1〜17のいずれか一項に記載の化粧品組成物。
- 前記皮膚疾患又は状態がざ瘡である、請求項18に記載の化粧品組成物。
- 前記皮膚疾患又は状態がしわである、請求項18に記載の化粧品組成物。
- 前記皮膚疾患又は状態が脂漏性皮膚炎である、請求項18に記載の化粧品組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697631P | 2012-09-06 | 2012-09-06 | |
US61/697,631 | 2012-09-06 | ||
US13/906,673 | 2013-05-31 | ||
US13/906,673 US8673325B1 (en) | 2012-09-06 | 2013-05-31 | Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same |
PCT/IB2013/058321 WO2014037903A2 (en) | 2012-09-06 | 2013-09-05 | Cosmetic compositions comprising epa and gla and methods of making and using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018243855A Division JP2019073526A (ja) | 2012-09-06 | 2018-12-27 | Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015527389A JP2015527389A (ja) | 2015-09-17 |
JP2015527389A5 JP2015527389A5 (ja) | 2017-01-19 |
JP6499965B2 true JP6499965B2 (ja) | 2019-04-10 |
Family
ID=50188375
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015530537A Active JP6499965B2 (ja) | 2012-09-06 | 2013-09-05 | Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 |
JP2018243855A Pending JP2019073526A (ja) | 2012-09-06 | 2018-12-27 | Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018243855A Pending JP2019073526A (ja) | 2012-09-06 | 2018-12-27 | Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8673325B1 (ja) |
EP (1) | EP2892616B1 (ja) |
JP (2) | JP6499965B2 (ja) |
CN (2) | CN104994911B (ja) |
AU (1) | AU2013311238B2 (ja) |
CA (1) | CA2882850C (ja) |
ES (1) | ES2829589T3 (ja) |
HK (1) | HK1211526A1 (ja) |
WO (1) | WO2014037903A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10602118B2 (en) * | 2015-12-02 | 2020-03-24 | Purdue Research Foundation | Method and system for multi-wavelength depth encoding for three dimensional range geometry compression |
JP6729678B2 (ja) | 2016-02-26 | 2020-07-22 | 日本電気株式会社 | 情報処理装置、容疑者情報生成方法及びプログラム |
KR102175655B1 (ko) * | 2019-04-03 | 2020-11-06 | 연세대학교 원주산학협력단 | 페길레이션된 아이코사펜타엔산 유도체, 이의 제조 방법 및 이를 포함하는 피부 노화 방지용 조성물 |
CN111529543A (zh) * | 2019-12-31 | 2020-08-14 | 蓝脑科技(厦门)有限公司 | 抗痤疮的岩藻黄质-琼胶寡糖组合物、制备方法及其应用 |
MX2022016144A (es) * | 2020-06-23 | 2023-02-13 | Unilever Ip Holdings B V | Composicion cosmetica para mejorar la apariencia de la piel. |
CN114931570A (zh) * | 2022-05-30 | 2022-08-23 | 广东省农业科学院动物卫生研究所 | 一种具有治疗动物脂溢性皮炎功能的产品及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04507397A (ja) * | 1988-01-14 | 1992-12-24 | フリッツ,アンデルス | 湿疹治療用薬剤製造における必須脂肪酸の使用法 |
CA1334002C (en) * | 1988-09-28 | 1995-01-17 | Barry D. Sears | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals |
US5059622A (en) * | 1989-08-29 | 1991-10-22 | Biosyn, Inc. | Method for reducing blood pressure levels in hypertensive persons |
KR930006432B1 (ko) | 1991-04-10 | 1993-07-16 | 주식회사 우방랜드 | 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물 |
JP3170024B2 (ja) * | 1992-02-03 | 2001-05-28 | サンスター株式会社 | 美白化粧料 |
JP3231075B2 (ja) * | 1992-04-03 | 2001-11-19 | 株式会社コーセー | 皮膚老化防止用化粧料 |
DE4238869C2 (de) * | 1992-11-18 | 1994-09-08 | Wogepharm Gmbh | Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten |
US5409955A (en) | 1993-05-13 | 1995-04-25 | Bockow; Barry I. | Compositions and methods for inhibiting uterine contractility |
JPH0881325A (ja) * | 1994-09-09 | 1996-03-26 | Kose Corp | 化粧料 |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
JP2962702B2 (ja) * | 1998-02-13 | 1999-10-12 | 株式会社 シャローネ | 化粧料 |
JP2000191525A (ja) * | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
US20040043013A1 (en) * | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
NZ529339A (en) * | 2001-05-30 | 2004-08-27 | Laxdale Ltd | Coenzyme Q and eicosapentaenoic acid (EPA) |
JP2003073268A (ja) * | 2001-08-31 | 2003-03-12 | Almighty:Kk | 細胞賦活剤及びそれを含有する皮膚外用剤 |
AU2003284633B2 (en) * | 2002-11-22 | 2008-07-10 | Nippon Suisan Kaisha, Ltd. | External composition containing polyunsaturated fatty acid or its salt or ester |
US20090318557A1 (en) * | 2003-12-22 | 2009-12-24 | Stockel Richard F | Dermatological compositions |
DE102004031210A1 (de) * | 2004-06-28 | 2006-02-09 | Trommsdorff Gmbh & Co. Kg | MLV-Kosmetikum |
JP2005139070A (ja) * | 2003-11-04 | 2005-06-02 | Kanebo Cosmetics Inc | 皮膚化粧料 |
JP2005179211A (ja) * | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
GB2409644B (en) * | 2003-12-31 | 2005-12-21 | Igennus Ltd | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof |
US20060009522A1 (en) * | 2004-07-01 | 2006-01-12 | Reza Dana | Compositions and methods for treating eye disorders and conditions |
US20060172012A1 (en) * | 2005-01-28 | 2006-08-03 | Finley John W | Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
ITMI20061672A1 (it) * | 2006-09-01 | 2008-03-02 | Altergon Sa | Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita' |
CN102209535B (zh) * | 2008-11-11 | 2013-03-27 | 希格马托制药工业公司 | 用于治疗橘皮组织的化合物 |
-
2013
- 2013-05-31 US US13/906,673 patent/US8673325B1/en active Active
- 2013-09-05 CN CN201380054837.8A patent/CN104994911B/zh active Active
- 2013-09-05 JP JP2015530537A patent/JP6499965B2/ja active Active
- 2013-09-05 EP EP13792454.4A patent/EP2892616B1/en active Active
- 2013-09-05 ES ES13792454T patent/ES2829589T3/es active Active
- 2013-09-05 AU AU2013311238A patent/AU2013311238B2/en active Active
- 2013-09-05 WO PCT/IB2013/058321 patent/WO2014037903A2/en unknown
- 2013-09-05 CN CN201811199409.5A patent/CN109157428A/zh active Pending
- 2013-09-05 CA CA2882850A patent/CA2882850C/en active Active
- 2013-09-06 US US14/020,176 patent/US9192674B2/en active Active
-
2015
- 2015-12-17 HK HK15112411.9A patent/HK1211526A1/xx unknown
-
2018
- 2018-12-27 JP JP2018243855A patent/JP2019073526A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2015527389A (ja) | 2015-09-17 |
US8673325B1 (en) | 2014-03-18 |
US9192674B2 (en) | 2015-11-24 |
AU2013311238A1 (en) | 2015-03-05 |
CA2882850C (en) | 2022-05-03 |
JP2019073526A (ja) | 2019-05-16 |
HK1211526A1 (en) | 2016-05-27 |
US20140066509A1 (en) | 2014-03-06 |
EP2892616B1 (en) | 2020-08-05 |
CN104994911A (zh) | 2015-10-21 |
CN104994911B (zh) | 2018-11-27 |
WO2014037903A2 (en) | 2014-03-13 |
CN109157428A (zh) | 2019-01-08 |
WO2014037903A3 (en) | 2014-07-31 |
AU2013311238B2 (en) | 2018-02-22 |
CA2882850A1 (en) | 2014-03-13 |
ES2829589T3 (es) | 2021-06-01 |
EP2892616A2 (en) | 2015-07-15 |
US20140066507A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6499965B2 (ja) | Epa及びglaを含む化粧品組成物、並びにその製造方法及び使用方法 | |
RU2712152C1 (ru) | Композиции для уменьшения раздражения за счет синергетического действия таурина и алоэ и связанные с ними способы | |
JPH08501553A (ja) | 皮膚調整組成物,その応用及び製造 | |
EP1891929A1 (en) | Skin cosmetic and wrinkle-reducing agent | |
AU2015247418A1 (en) | Methods and compositions for topical delivery for skin care | |
WO2018084112A1 (ja) | アクネ菌株選択的抗菌剤 | |
JP2008222653A5 (ja) | ||
JP4579564B2 (ja) | シワ改善剤 | |
EP2549976A2 (de) | Hautfreundliche wirkstoffkombination gegen akne | |
JP2019065004A (ja) | 皮膚常在細菌叢改善剤及びこれを含有する化粧料又は皮膚外用剤 | |
JP2013023437A (ja) | ヒアルロン酸産生促進剤 | |
JP2008222651A5 (ja) | ||
JP4488933B2 (ja) | シワ改善剤及び皮膚外用組成物 | |
JP2001322990A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
EP4084789A1 (en) | Ppar agonist complex and methods of use | |
ES2780900T3 (es) | Nueva utilización de compuestos de perfumería contra el rebrote de pelo | |
JP2010030932A (ja) | 皮膚外用剤 | |
US11633425B2 (en) | Anti-glycation compositions | |
DE102019205767A1 (de) | Deodorant- oder Antitranspirantzusammensetzung | |
CN114867464A (zh) | 局部化妆品组合物、所述组合物和用于面部施用滋补剂的用途 | |
JP5768114B2 (ja) | エージング対応用の皮膚外用剤の製造方法 | |
JP2008222650A5 (ja) | ||
JP2001322930A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160902 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161130 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170705 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180815 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181227 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6499965 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |